A Phase 2 interventional study of bevacizumab injection and bevacizumab injection in Recurrent and Hemorrhage, sponsored by University of Sao Paulo. Status unknown at 1 site in Brazil. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-06-28.
Sponsored by University of Sao Paulo · Phase 2, Interventional, and Prevention
Postoperative vitreous hemorrhage is a common complication after vitrectomy for proliferative diabetic retinopathy. There have been efforts to lower the incidence of postoperative vitreous hemorrhage such as preoperative bevacizumab injection. Bevacizumab (Avastin) is a potent inhibitor of angiogenesis and has been shown to decrease retinal and iris neovascularization in proliferative diabetic retinopathy. Recently there have been reports showing that preoperative bevacizumab injection could reduce intraoperative bleeding from abnormal vessels and could make surgery easier and more successful. Our hypothesis is that intraoperative bevacizumab injection could reduce postoperative vitreous hemorrhage by inhibiting the vessel formation after surgery.
We started the prospective randomized comparative study to determine the effect of pre and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy in comparison to vitrectomy without any adjuvant drug.
41 studies on the registry are indexed under Vitreous Hemorrhage; 3 are open to participants now.
This study's planned enrollment of 2 is below the median of 61 across 33 interventional studies indexed under Vitreous Hemorrhage.
Browse Vitreous Hemorrhage studies →University of Sao Paulo is the lead sponsor of 1,005 studies on the registry; 90 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
no bevacizumab
bevacizumab before vitrectomy
Procedure: bevacizumab injection
bevacizumab after vitrectomy
Procedure: bevacizumab injection
bevacizumab injection before vitrectomy
bevacizumab injection after vitrectomy
Vitreous hemorrhage recurrence
Time frame: 3 months
This study is status unknown, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Sao Paulo